Ruxolitinib: a targeted treatment option for patients with polycythemia vera

por Vaddi, Kris, Verstovsek, Srdan, Kiladjian, Jean-Jacques
Publicado 2016

Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes

por Mughal, Tariq I, Vaddi, Kris, Sarlis, Nicholas J, Verstovsek, Srdan
Publicado 2014

Discovery of Potent and Selective Covalent Protein Arginine Methyltransferase 5 (PRMT5) Inhibitors

por Lin, Hong, Wang, Min, Zhang, Yang W., Tong, Shuilong, Leal, Raul A., Shetty, Rupa, Vaddi, Kris, Luengo, Juan I.
Publicado 2019

Oral arsenic trioxide ORH-2014 pharmacokinetic and safety profile in patients with advanced hematologic disorders

por Ravandi, Farhad, Koumenis, Iphigenia, Johri, Anandhi, Tallman, Martin, Roboz, Gail J., Strickland, Stephen, Garcia-Manero, Guillermo, Borthakur, Gautam, Naqvi, Kiran, Meyer, Meghan, Pudipeddi, Madhu, Nidarmarthy, Sirish, Vaddi, Kris, Kantarjian, Hagop
Publicado 2020

Validation of protein arginine methyltransferase 5 (PRMT5) as a candidate therapeutic target in the spontaneous canine model of non-Hodgkin lymphoma

por Sloan, Shelby L., Renaldo, Kyle A., Long, Mackenzie, Chung, Ji-Hyun, Courtney, Lindsay E., Shilo, Konstantin, Youssef, Youssef, Schlotter, Sarah, Brown, Fiona, Klamer, Brett G., Zhang, Xiaoli, Yilmaz, Ayse S., Ozer, Hatice G., Valli, Victor E., Vaddi, Kris, Scherle, Peggy, Alinari, Lapo, Kisseberth, William C., Baiocchi, Robert A.
Publicado 2021

Targeting OXPHOS de novo purine synthesis as the nexus of FLT3 inhibitor–mediated synergistic antileukemic actions

por Zhang, Pu, Brinton, Lindsey T., Gharghabi, Mehdi, Sher, Steven, Williams, Katie, Cannon, Matthew, Walker, Janek S., Canfield, Daniel, Beaver, Larry, Cempre, Casey B., Phillips, Hannah, Chen, Xuyong, Yan, Pearlly, Lehman, Amy, Scherle, Peggy, Wang, Min, Vaddi, Kris, Baiocchi, Robert, Wang, Ruoning, Sampath, Deepa, Alinari, Lapo, Blachly, James S., Lapalombella, Rosa
Publicado 2022

PRMT5 inhibition drives therapeutic vulnerability to combination treatment with BCL-2 inhibition in mantle cell lymphoma

por Brown-Burke, Fiona, Hwang, Inah, Sloan, Shelby, Hinterschied, Claire, Helmig-Mason, JoBeth, Long, Mackenzie, Chan, Wing Keung, Prouty, Alexander, Chung, Ji-Hyun, Zhang, Yang, Singh, Satishkumar, Youssef, Youssef, Bhagwat, Neha, Chen, Zhengming, Chen-Kiang, Selina, Di Liberto, Maurizio, Elemento, Olivier, Sehgal, Lalit, Alinari, Lapo, Vaddi, Kris, Scherle, Peggy, Lapalombella, Rosa, Paik, Jihye, Baiocchi, Robert A.
Publicado 2023

Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies

por Koblish, Holly, Li, Yun-long, Shin, Niu, Hall, Leslie, Wang, Qian, Wang, Kathy, Covington, Maryanne, Marando, Cindy, Bowman, Kevin, Boer, Jason, Burke, Krista, Wynn, Richard, Margulis, Alex, Reuther, Gary W., Lambert, Que T., Dostalik Roman, Valerie, Zhang, Ke, Feng, Hao, Xue, Chu-Biao, Diamond, Sharon, Hollis, Greg, Yeleswaram, Swamy, Yao, Wenqing, Huber, Reid, Vaddi, Kris, Scherle, Peggy
Publicado 2018

Dysregulation of PRMT5 in chronic lymphocytic leukemia promotes progression with high risk of Richter’s transformation

por Hing, Zachary A., Walker, Janek S., Whipp, Ethan C., Brinton, Lindsey, Cannon, Matthew, Zhang, Pu, Sher, Steven, Cempre, Casey B., Brown, Fiona, Smith, Porsha L., Agostinelli, Claudio, Pileri, Stefano A., Skinner, Jordan N., Williams, Katie, Phillips, Hannah, Shaffer, Jami, Beaver, Larry P., Pan, Alexander, Shin, Kyle, Gregory, Charles T., Ozer, Gulcin H., Yilmaz, Selen A., Harrington, Bonnie K., Lehman, Amy M., Yu, Lianbo, Coppola, Vincenzo, Yan, Pearlly, Scherle, Peggy, Wang, Min, Pitis, Philip, Xu, Chaoyi, Vaddi, Kris, Chen-Kiang, Selina, Woyach, Jennifer, Blachly, James S., Alinari, Lapo, Yang, Yiping, Byrd, John C., Baiocchi, Robert A., Blaser, Bradley W., Lapalombella, Rosa
Publicado 2023